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Yellow fever (YF) is a lethal viral disease that is endemic in some tropical regions of South America, Central 
America and Africa. An attenuated vaccine produced in embryonated eggs is available since the 1930’s and is 
known to be highly effective and safe. However, after large vaccination campaigns in the 2000’s, reports of rare, 
but serious adverse events have stimulated Biomanguinhos/FIOCRUZ, who produces the current attenuated 
17DD vaccine, to develop a new, inactivated vaccine. 
 
Over the last years, through a partnership of the Federal University of Rio de Janeiro and 
Biomanguinhos/FIOCRUZ, both upstream and downstream processes were developed. The upstream process 
was established based on Vero cell cultivation on microcarriers in serum-free medium, using stirred-tank 
bioreactors. The first studies were carried out in spinner flasks to select the microcarrier type and the serum-free 
medium. Also, statistical DOE tools were used to study the infection step, varying the moiety of infection and the 
time of infection. This process was then scale-up to stirred-tank bioreactors and further optimized regarding 
microcarrier concentration, stepwise medium addition, dissolved oxygen level/sparging intensity, impeller 
configuration and time of harvest. The final upstream process that was established results in virus titers of 10^8 
pfu/mL within a time frame 144h post inoculation of the cells in the bioreactor. 
 
The downstream process was designed priorizing chromatographic techniques, aiming at achieving high purity 
levels and extensive removal of process-related critical contaminants, such as DNA and host-cell proteins 
(HCP), as preconized by the regulatory authorities. For the capture step, both cation- and anion-exchange 
chromatographies were evaluated. A Q membrane adsorber process was selected and the best operational 
conditions in terms of pH, temperature, buffers and washing strategies were determined. For the second 
purification step, three techniques were evaluated: multimodal chromatography, ultrafiltration/diafiltration, and 
hydrophobic interaction chromatography using a HIC membrane adsorber. The multimodal resin showed the 
best results, and operational conditions of this step were further optimized. The final 2-step yellow-fever virus 
purification process resulted in an overall yield of 52% and residual HCP of 350 ppm (0.05%). Residual DNA 
was 1.2 ng per dose, considering the dose established based on animal studies, and is in agreement with the 
limit recommended by the World Health Organization (<10 ng/dose). Electrophoretic analysis (SDS-PAGE) of 
the purified samples showed a band corresponding to 96% of identified proteins with molecular mass of 56 kDa, 
which is the expected mass for the virus envelope protein (E). Anti-E Western blot (WB) showed a single band, 
confirming the identity of the samples. No band was revealed in the anti-HCP blot, confirming the low HCP 
levels quantified. 
 
The developed process allows the production of a new, high-purity yellow-fever vaccine through a scalable 
technology, which is better suited than egg-based technology to meet emergency demands in case of epidemics 
and is useful in the current scenario of increasing worldwide demand YF vaccine. 
 
 
